Synbodies for detection of human norovirus

Abstract

Synbodies specific for Norovirus and coupled with a substrate provide Norovirus binding and detection platforms (FIG. 1). A Norovirus capturing platform, comprising one or more synbodies selected from the group consisting of synbodies 6-6, 92-92, 93-93, and 94-94 coupled to a substrate, has been found to found to bind with either GII.4 Minerva or both GII.4 Minerva and GII.4 Sydney# strains of norovirus.

Description

BACKGROUND OF THE INVENTION

Norovirus, a Calicivirus (family Caliciviridae), is colloquially known as “stomach flu” or “food poisoning”. Norovirus is recognized as one of the major causes of nonbacterial outbreaks worldwide. This accounts for an estimated of 23 million infections per year in the US (the second highest cause of nonbacterial gastroenteritis (GE) morbidity) and imposes a substantial burden on healthcare.

Norovirus is classified as “NIAID category B Priority bio-defense Pathogen”. It is a non-enveloped, single-stranded, positive sense RNA genome which is environmentally stable due to capsid formation. It can resist freezing and heating to up to 60 C and is stable at low concentrations of chlorine. An infectious dose of 10-100 viruses via fecal-oral transmission or droplet transmission can lead to infection. This is a highly contagious but short-lived illness (48 hrs) causes vomiting, stomach pain and diarrhea. Also, it can cause chronic infections in transplant recipient.

Of the five geno-groups of Norovirus, GI, GII, and GIV are known to infect humans. There is no available vaccine for human Norovirus infection, with progress being hampered by the absence of suitable animal model/cell culture for preclinical testing of the candidate vaccine. Presently, the detection of viral RNA is limited to RT-PCR in the stool samples of affected humans.

SUMMARY OF THE INVENTION

The embodiments disclosed herein generally relate to the creation of synbodies for Norovirus and to simple, practical, and broadly reactive methods to detect human Norovirus in relevant non-clinical sample matrices (e.g., food, water, and environment).

These and other aspects of the invention will be apparent upon reference to the following detailed description and figures. To that end, any patent and other documents cited herein are hereby incorporated by reference in their entirety.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates an overview of the identification of lead peptide candidates.

FIG. 2 depicts a heat MAP of the Optimization of lead peptide candidates for nVLP GII.4.

FIG. 3 depicts surface plasmon resonance screening of optimized peptides.

FIG. 4 depicts nVLPGII.4 synbody construction.

FIG. 5 depicts an ELISA screening of nVLPGII.4 synbodies.

FIG. 6 depicts nVLP (GII.4) synbodies with K_D<50 nM.

FIG. 7 depicts the ELISA based detection of human Norovirus.

FIG. 8 depicts the enrichment of GII.4 Minerva VLP captured from a dilute solution using synbody 93-93.

DETAILED DESCRIPTION OF THE INVENTION

Embodiments of the invention relate to peptide affinity ligands (synbodies) for the detection of human Norovirus. As a first step to creating a synbody, a virus-like particle (VLP) was used as a Norovirus surrogate. The Norovirus surrogate VLP (nVLP) assembled from capsid structural subunits antigenically resembles native virus yet lacks viral nucleic acid, thereby rendering it non-infectious. The nVLP can be produced in a variety of known prokaryotic and eukaryotic expression systems to provide an ample sample supply.

To engineer peptide affinity ligands for nVLP, peptides specific for nVLP were identified by screening cell lysate from baculovirus expression and transgenic tobacco expression of nVLP (type GII.4 Minerva strain) against a library of 10,000 20mer peptides of random sequences in microarray format. Three lead peptides were identified. With an aim to detect very low amount of virus coat protein present in complex mixture, we focused on improving the affinity and specificity of the identified lead peptides for nVLP GII.4 (FIGS. 1 and 2).

For this, nine amino acids (Y, A, D, S, K, N, V, W, E) were selected and an amino acid point variant peptide library for each selected lead peptide was designed. These peptides (408 in all) were printed on microarrays using similar sulfhydryl chemistry as used in the 10,000 peptide microarrays and screened against nVLP GII.4. After amino acid substitutions for increased binding affinity for nVLP GII.4 were identified, a library of optimized peptides (96) was created by the addition of 5-7 amino acid combinations.

These 96 peptides were synthesized and tested unpurified against GII.4 via surface plasmon resonance (SPR), a sample of which is shown in FIG. 3. Peptides candidates were analyzed and selected for improved binding and slower dissociation rate. Finally, a list of 10 peptide candidates with improved binding and slower dissociation rates were chosen to construct bivalent peptide affinity reagents (synbodies).

TABLE-1
Selected Peptides candidates for Synbody Construction
			Avg
SEQ			Binding
ID	Peptide		(Spot	%	kd-1
NO.	Code	Selected Peptides	1/2)	Stability	(sec)
1	nVLP-1WT	LLYNKTFPHGRWSPSYPGSC	71.5	25%	7.85E-03
2	nVLP-2WT	DWARSNTSRSMDFNLGWGSC	2.5	—	2.33E-02
3	Mut Peptide-81	AWARSNNSRSKAFNLGWGSC	127.9	45%	4.55E-03
4	Mut Peptide-60	DWARKNNKRKMNFNLGWGSC	134.3	44%	4.87E-03
5	Mut Peptide-53	VWARKNNKRKKDFNAGWGSC	188.8	51%	4.08E-03
6	Mut Peptide-78	SWARSNNKRSKAFNLGWGSC	168.8	46%	4.31E-03
7	nVLP-6WT	RWHRVDLRSHTELPRYIGSC	175.7	37%	5.13E-03
8	Mut Peptide-92	RWHRVKLRSHTELNRYIGSC	229.5	57%	3.55E-03
9	Mut Peptide-93	RWVRVKLRSHTELNRYIGSC	274.2	60%	3.32E-03
10	Mut Peptide-94	RWVRVKLRSHTKLRYIGSC	358.2	63%	2.94E-03

Construction of Peptide Affinity Reagents (Synbody) for nVLP GII.4:

Two scaffolds (scaffold-1571 and scaffold-MAP-2) with maleimide functional groups were selected for synbody construction (see, for example, FIG. 4). Peptide candidates (Table 1) were constrained on two scaffolds via sulfhydryl coupling. A total of 53 synbody conjugation reactions were carried out on two different scaffold types and 98 synbodies were recovered after HPLC purification. Synbodies were characterized by a matrix-assisted laser desorption/ionization time-of-flight mass spectrometer (MALDI-TOF) and tested against purified GII.4 nVLP binding in a direct ELISA assay (FIG. 5). Table 2 and FIG. 6 show synbodies with K_D<50 nM.

TABLE-2
nVLP (GII.4) Synbodies with KD < 50 nM
nVLP Synbodies for GII.4
SEQ ID
NO.	Synbody	Synbody Sequence	Scaffold	ELISA KD
11	nVLP6-6-1571	RWHRVDLRSHTELPRYIGSC-RWHRVDLRSHTELPRYIGSC-1571	1571	2 nM
12	nVLP6-53-1571	RWHRVDLRSHTELPRYIGSC-VWARKNNKRKKDFNAGWGSC-1571	1571	1 nM
13	nVLP6-78-1571	RWHRVDLRSHTELPRYIGSC-SWARSNNKRSKAFNLGWGSC-1571	1571	2 nM
14	nVLP6-92-1571	RWHRVDLRSHTELPRYIGSC-RWHRVKLRSHTELNRYIGSC-1571	1571	2 nM
15	nVLP6-60-1571	RWHRVDLRSHTELPRYIGSC-DWARKNNKRKMNFNLGWGSC-1571	1571	3 nM
16	nVLP6-81-1571	RWHRVDLRSHTELPRYIGSC-RWHRVDLRSHTELPRYIGSC-1571	1571	3 nM
17	nVLP6-94-1571	RWHRVDLRSHTELPRYIGSC-RWHRVDLRSHTELPRYIGSC-1571	1571	1 nM
18	nVLP2-53-1571	DWARSNTSRSMDFNLGWGSC-VWARKNNKRKKDFNAGWGSC-1571	1571	20 nM
19	nVLP2-78-1571	DWARSNTSRSMDFNLGWGSC-SWARSNNKRSKAFNLGWGSC-1571	1571	25 nM
20	nVLP2-92-1571	DWARSNTSRSMDFNLGWGSC-RWHRVKLRSHTELNRYIGSC-1571	1571	15 nM
21	nVLP2-60-1571	DWARSNTSRSMDFNLGWGSC-DWARKNNKRKMNFNLGWGSC-1571	1571	10 nM
22	nVLP2-81-1571	DWARSNTSRSMDFNLGWGSC-AWARSNNSRSKAFNLGWGSC-1571	1571	40 nM
23	nVLP2-92-1571	DWARSNTSRSMDFNLGWGSC-RWHRVKLRSHTELNRYIGSC-1571		10 nM
24	nVLP2-93-1571	DWARSNTSRSMDFNLGWGSC-RWVRVKLRSHTELNRYIGSC-1571		5 nM
25	nVLP2-94-1571	DWARSNTSRSMDFNLGWGSC-RWVRVKLRSHTKLNRYIGSC-1571	1571	5 nM
26	nVLP1-53-1571	LLYNKTFPHGRWSPSYPGSC-VWARKNNKRKKDFNAGWGSC-1571	1571	19 nM
27	nVLP1-55-1571	LLYNKTFPHGRWSPSYPGSC-VWARKNNSRSKDFNAGWGSC-1571	1571	7 nM
28	nVLP1-72-1571	LLYNKTFPHGRWSPSYPGSC-SWARSNNSRSMDFNLGWGSC-1571	1571	15 nM
29	nVLP1-93-1571	LLYNKTFPHGRWSPSYPGSC-RWVRVKLRSHTELNRYIGSC-1571	1571	4 nM
30	nVLP1-94-1571	LLYNKTFPHGRWSPSYPGSC-RWVRVKLRSHTKLNRYIGSC-1571	1571	6 nM
31	nVLP60-60-1571	DWARKNNKRKMNFNLGWGSC-DWARKNNKRKMNFNLGWGSC-1571	1571	2 nM
32	nVLP81-81-1571	AWARSNNSRSKAFNLGWGSC-AWARSNNSRSKAFNLGWGSC-1571	1571	3 nM
33	nVLP93-93-1571	RWVRVKLRSHTELNRYIGSC-RWVRVKLRSHTELNRYIGSC-1571	1571	4 nM
34	nVLP78-78-1571	SWARSNNKRSKAFNLGWGSC-SWARSNNKRSKAFNLGWGSC-1571	1571	5 nM
35	nVLP92-92-1571	RWHRVKLRSHTELNRYIGSC-RWHRVKLRSHTELNRYIGSC-1571	1571	3 nM
36	nVLP94-94-1571	RWVRVKLRSHTKLNRYIGSC-RWVRVKLRSHTKLNRYIGSC-1571	1571	1 nM
37	nVLP53-53-1571	VWARKNNKRKKDFNAGWGSC-VWARKNNKRKKDFNAGWGSC-1571	1571	1 nM
38	nVLP55-55-1571	VWARKNNSRSKDFNAGWGSC-VWARKNNSRSKDFNAGWGSC-1571	1571	9 nM
39	nVLP1-1-MAP2	LLYNKTFPHGRWSPSYPGSC-LLYNKTFPHGRWSPSYPGSC-MAP2	MAP-2	4 nM
40	nVLP1-53-MAP2	LLYNKTFPHGRWSPSYPGSC-LLYNKTFPHGRWSPSYPGSC-MAP2	MAP-2	2 nM
41	nVLP1-60-MAP2	LLYNKTFPHGRWSPSYPGSC-LLYNKTFPHGRWSPSYPGSC-MAP2	MAP-2	5 nM
42	nVLP1-78-MAP2	LLYNKTFPHGRWSPSYPGSC-LLYNKTFPHGRWSPSYPGSC-MAP2	MAP-2	7 nM
43	nVLP1-81-MAP2	LLYNKTFPHGRWSPSYPGSC-LLYNKTFPHGRWSPSYPGSC-MAP2	MAP-2	7 nM
44	nVLP1-92-MAP2	LLYNKTFPHGRWSPSYPGSC-LLYNKTFPHGRWSPSYPGSC-MAP2	MAP-2	8 nM
45	nVLP1-94-MAP2	LLYNKTFPHGRWSPSYPGSC-LLYNKTFPHGRWSPSYPGSC-MAP2	MAP-2	1 nM
46	nVLP2-53-MAP2	DWARSNTSRSMDFNLGWGSC-VWARKNNKRKKDFNAGWGSC-MAP2	MAP-2	5 nM
47	nVLP2-92-MAP2	DWARSNTSRSMDFNLGWGSC-RWHRVKLRSHTELNRYIGSC-MAP2	MAP-2	34 nM
48	nVLP6-6MAP2	RWHRVDLRSHTELPRYIGSC-RWHRVDLRSHTELPRYIGSC-MAP2	MAP-2	39 nM
49	nVLP6-53-MAP2	RWHRVDLRSHTELPRYIGSC-VWARKNNKRKKDFNAGWGSC-MAP2	MAP-2	0 nM
50	nVLP6-81-MAP2	RWHRVDLRSHTELPRYIGSC-AWARSNNSRSKAFNLGWGSC-MAP2	MAP-2	40 nM
51	nVLP6-92-MAP2	RWHRVDLRSHTELPRYIGSC-RWHRVKLRSHTELNRYIGSC-MAP2	MAP-2	33 nM
52	nVLP6-93-MAP2	RWHRVDLRSHTELPRYIGSC-RWVRVKLRSHTELNRYIGSC-MAP2	MAP-2	50 nM

ELISA Detection.

A direct ELISA method for detection of HuNoV also has been developed. Stool samples containing HuNoV (GII.3, GII.4, or no NoV) were coated onto an ELISA plate and detected with a fixed concentration of the candidate synbody. Initial results clearly indicate that the synbody performs similarly to a polyclonal antibody raised against the GII.4 strain (FIG. 7).

As shown in FIG. 8 and Table 3, enrichment of either GII.4 Minerva or both GII.4 Minerva and GII.4 Sydney# occurs for synbodies 6-6, 92-92, 93-93, and 94-94 from Table 2.

TABLE 3
Enrichment of two different Norovirus
VLPs captured from a dilute solution.
	VP1 Protein	Enrichment Factor from 1 ng/μL solution
	Identity	Syn 6-6	Syn 92-92	Syn 93-93	Syn 94-94
GII.4	100%	16	3	10	7
Minerva
GII.4	95%	n.e.	n.e.	3	3
Sydney#

In view of the above, a series of affinity agents for the detection of Norovirus have been developed. These synbodies can be used for detection of Norovirus or in capture assays for Norovirus concentration or enrichment. These Norovirus detecting synbodies can be coupled with filtration procedures, which may be used to remove low levels of viruses present in naturally contaminated surfaces or samples.

The claims are not intended to be limited to the embodiments and examples described herein.

Claims

1. A norovirus detection agent selected from the group consisting of synbodies 6-6 (SEQ ID NO:11), 92-92 (SEQ ID NO:35), 93-93 (SEQ ID NO:33), and 94-94 (SEQ ID NO:36).

2. A Norovirus capturing platform, comprising one or more synbodies selected from the group consisting of synbodies 6-6 (SEQ ID NO:11), 92-92 (SEQ ID NO:35), 93-93 (SEQ ID NO:33), and 94-94 (SEQ ID NO:36) coupled to a substrate.

3. A method for binding Norovirus, comprising the steps of coupling one or more synbodies of claim 1 to a substrate and contacting said substrate with a sample.

4. The norovirus detection agent of claim 1, wherein said agent is synbody 6-6 (SEQ ID NO:11).

5. The norovirus detection agent of claim 1, wherein said agent is synbody 92-92 (SEQ ID NO:35).

6. The norovirus detection agent of claim 1, wherein said agent is synbody 93-93 (SEQ ID NO:33).

7. The norovirus detection agent of claim 1, wherein said agent is synbody 94-94 (SEQ ID NO:36).

8. The method for binding Norovirus of claim 3, wherein said agent is synbody 6-6 (SEQ ID NO:11).

9. The method for binding Norovirus of claim 3, wherein said agent is synbody 92-92 (SEQ ID NO:35).

10. The method for binding Norovirus of claim 3, wherein said agent is synbody 93-93 (SEQ ID NO:33).

11. The method for binding Norovirus of claim 3, wherein said agent synbody 94-94 (SEQ ID NO:36).